Found 25 results for Lung Disease
A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
A Randomized Phase III Trial Incorporating Pathologic Complete Response in Participants with Early Stage Non Small Cell Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (Insight)
R
Rohan Maniar
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells …
Analysis of DRC in lung disease
C
Catherine Sears, MD
The DNA repair capacity (DRC) is a measure of a cell’s ability to repair DNA damage. High levels of DNA damage are observed in many lung diseases, including lung cancer and chronic obstructive lung disease (COPD, sometimes referred to as emphysema or chronic bronchitis). We believe that patients with a …
Phase I/II Trial of Lurbinectedin with Osimertinib in Transformed Small Cell Lung Cancer
M
Misty D. Shields, MD, PhD
Primary Objective:To assess the efficacy of the combination of lurbinectedin with osimertinib in patients with EGFR altered non-small cell lung cancer (NSCLC) with documented transformation to SCLC, after the use of EGFR tyrosine kinase inhibitor osimertinib.Secondary ObjectiveTo evaluate the safety of the combination of lurbinectedin with osimertinib in patients with …
A Phase II Study of Amivantamab SC (subcutaneous) in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
R
Rohan Maniar
What is the purpose of this study?This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-SC …
Rapid Autopsy Protocol for Patients with Small Cell Lung Cancer
S
Shadia Jalal, MD
This is pilot study to establish a rapid autopsy program in Small Cell Lung Cancer (SCLC) at the Indiana University Simon Comprehensive Cancer Center and outline the components necessary for tumor tissue collection. This proposal is a collaboration between scientists, lung cancer physicians, pathologists, and the IUSCCC Translational Research Core. …
Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
N
Nasser Hanna, MD
This research aims to incorporate ctDNA analysis into clinical practice to individualize therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach (as opposed to treatment based on clinical or radiographic evidence of disease). Interested in participating? For more information about this research study or other cancer-related …
Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer
T
Tim Lautenschlaeger
There has been evidence that patients being treated with chemoradiation for Non-Small Cell Lung Cancer (NSCLC) have experienced cardiac toxicities (heart damage). This study is exploring if testing patients hearts that have been diagnosed with NSCLC before and after treatment can help investigators decrease heart damage for patients in the …
Exploring Treatment Options After Lung Cancer Surgery
V
Vijaya L. Kakani, MD
Do you have non-small cell lung cancer (NSCLC) but the cancer was not fully removed by surgery? You may qualify for a study exploring treatment options for NSCLC.This research study is testing whether adding a medication called sacituzumab tirumotecan to pembrolizumab after surgery may help prevent non-small cell lung cancer …
An Open-Label, Randomized Study of Bms-986489 (Atigotatug + Nivolumab Fixed-Dose Combination) Vs Durvalumab as Consolidation Therapy Following Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (Tigos-Ls)
M
Misty D. Shields, MD, PhD
This is an open-label, randomized study of BMS-986489 (atigotatug + nivolumab fixed-dose combination) vs durvalumab in limited-stage (LS)-small-cell lung cancer (SCLC) participants.The main goals of this study are to:Evaluate the efficacy of BMS-986489 vs durvalumabEvaluate the safety profile of BMS-986489Interested in participating? For more information about this research study or …
Together for Tomorrow: Explore New Treatment Options for Lung Cancer
V
Vijaya L. Kakani, MD
We understand that living with non-small cell lung cancer (NSCLC), especially with the KRAS G12C mutation, can be incredibly challenging. Many people with lung cancer go through hard treatments and tough side effects. That's why we're inviting adults (ages 18 and older) who have advanced or metastatic nonsquamous NSCLC to participate …
Please choose between Voice or SMS based delivery of verification code
or